Zacks Investment Research
25 Jun 2026, 12:51 UTC · 16w ago
Impact · against what's priced in
Silence Therapeutics (SLN) shows strong short-term momentum driven by explosive expected revenue growth and anticipation for August 2026 phase II results for divesiran. While increasing losses are expected, the clinical potential of its siRNA therapy is the primary value driver.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Silence Therapeutics (SLN) shares surged 26% to $9.16 in the last trading session on high volume.
More positive than 81% of claims this week
Silence Therapeutics expects revenue of $3.14 million for the upcoming quarter, a 1325% increase year-over-year.
Continue reading
5 related stories
The stock is reacting to a massive 1325% year-over-year expected revenue increase and the upcoming August 2026 topline results for the SANRECO phase II study of divesiran.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 69% of claims this week
Topline results for Silence Therapeutics' SANRECO phase II study for divesiran are expected in August 2026.
So whatClinical trial results are primary catalysts for biotech valuations, creating a specific future date for high volatility.
More positive than 57% of claims this week
Silence Therapeutics is expected to report a quarterly loss of $0.32 per share, a 40.7% increase year-over-year.
More negative than 67% of claims this week
Which stocks this story touches
More positive than 91% of ticker scores this week
Shares rose 26% on encouraging clinical data for its lead candidate and significant expected revenue growth.
More positive than 53% of ticker scores this week
The stock closed slightly higher and has shown a modest positive return over the past month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
4h ago
+113.6%
Price agrees with the score
$19.57 vs $9.16 close before publication (Jun 24) · not market-adjusted
SLN chart →
